- Home
- RSF vs MREO Comparison
RSF vs MREO Comparison
Compare RSF & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RSF | MREO |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.6M | 50.3M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | RSF | MREO |
|---|---|---|
| Price | $14.57 | $0.27 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 9.7K | ★ 849.2K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 10.61% | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | N/A | $5,184.20 |
| Revenue Next Year | N/A | $55.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.23 | $0.20 |
| 52 Week High | $15.07 | $2.37 |
Technical Indicators
Market Signals| Indicator | RSF | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 54.10 | 41.11 |
| Support Level | $14.51 | $0.28 |
| Resistance Level | $14.70 | $0.35 |
| Average True Range (ATR) | 0.06 | 0.03 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 78.81 | 7.70 |
Price Performance
Historical ComparisonAbout RSF RiverNorth Capital and Income Fund
RiverNorth Capital and Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income by investing in credit instruments, including a portfolio of securities of specialty finance and other financial companies.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).